UX023: Extension study data

Data from 22 patients with XLH who received once-monthly 0.1-1 mg/kg subcutaneous KRN23 in the 12-month, open-label INT-002 extension of the 4-month, open-label, dose-escalation, U.S. and Canadian Phase I/II INT-001 trial showed that increases in

Read the full 355 word article

How to gain access

Continue reading with a
two-week free trial.